First-Line Antibiotic for Spontaneous Bacterial Peritonitis
For community-acquired spontaneous bacterial peritonitis, initiate intravenous cefotaxime 2 g every 6-8 hours or ceftriaxone 1-2 g every 12-24 hours as first-line empirical therapy. 1, 2
Dosing Recommendations
Third-generation cephalosporins remain the gold standard for community-acquired SBP based on multiple guidelines:
- Cefotaxime: 2 g IV every 6-8 hours for 5-7 days 1, 2
- Ceftriaxone: 1-2 g IV every 12-24 hours for 5-7 days 1, 2
Both agents achieve high ascitic fluid concentrations and demonstrate 77-98% infection resolution rates with similar mortality outcomes 1, 2. The evidence shows 5-day treatment courses are as effective as 10-day regimens 1.
Alternative Options (Community-Acquired)
Amoxicillin-clavulanic acid (1 g/0.2 g IV every 8 hours) shows equivalent efficacy to cefotaxime with 87% resolution rates 1, 2.
Oral ofloxacin (400 mg twice daily) can be considered ONLY in uncomplicated cases without:
- Renal failure
- Hepatic encephalopathy
- Gastrointestinal bleeding
- Ileus or shock
- Prior quinolone exposure 2
Critical Caveat: Nosocomial and Healthcare-Associated SBP
Do NOT use third-generation cephalosporins as first-line for nosocomial or healthcare-associated SBP. 3 These infections require broad-spectrum coverage with carbapenems or piperacillin-tazobactam due to multidrug-resistant organisms.
Quinolone Resistance Warning
Avoid quinolones in patients with:
- Current quinolone prophylaxis
- Prior SBP episodes
- Nosocomial infection
- Areas with high quinolone resistance (>30% in some centers) 1, 3
The Korean data shows E. coli quinolone resistance reaching 31.7%, making fluoroquinolones increasingly unreliable 1.
Essential Adjunctive Therapy
Add IV albumin (1.5 g/kg at diagnosis, then 1 g/kg on day 3) to antibiotic therapy 2, 3. This combination reduces mortality from 29% to 10% (p=0.01) and prevents hepatorenal syndrome, particularly in patients with:
Treatment Response Assessment
Perform repeat paracentesis at 48 hours 3. Treatment failure is defined as <25% decrease in ascitic PMN count from baseline 2. If this occurs:
- Broaden antibiotic coverage immediately
- Obtain abdominal imaging to exclude secondary peritonitis
- Consider resistant organisms or nosocomial pathogens
Common Pitfall
The most frequent error is continuing third-generation cephalosporins in patients with risk factors for resistant organisms. Recent data shows only 18.7-59% primary response rates to cefotaxime in some cohorts 4, 5, with nosocomial SBP, recurrent SBP, and refractory ascites predicting treatment failure 4, 5. In these high-risk patients, escalate to broader coverage empirically rather than waiting for treatment failure.